Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Nessa Carey will lead the strategic development and implementation of the Entrepreneur in Residence (EiR) programme in Medical Sciences, laying the foundation of a world-class innovation support ecosystem capable of accelerating the translation of world-leading research into innovative therapies, business and commercial products.

Dr Nessa Carey and Royal Society (logo)

Managed by the MSD Translational Research Office (TRO), the scheme is designed to provide Oxford's research community with access to world-leading expertise and advice across multiple industry sectors in the following themes:

  • Development of compelling translational project/technology strategies
  • Navigating hurdles associated with commercialisation and spin-out, working alongside Oxford University Innovation
  • Sourcing and development of high quality bids for external funding streams

Dr Nessa Carey will bring broad, multi-stakeholder and non-sector specific strategic oversight to the programme. With experience of the biotechnology industry landscape, she has vast knowledge of business, IP and commercialisation strategies across biomedical modalities, and will work with Oxford's academic community to enrich innovative translational programmes with commercial context.

Dr Carey will also work with our Business Partnerships Office and Translational Research Office teams, as well as Oxford University Innovation, to facilitate the recruitment of ‘Experts’ with an in-depth sector-specific knowledge, which they will apply to research programmes to ensure routes to translation are optimised and potential hurdles identified early.

Find out more about the Entrepreneur in Residence scheme and Dr Nessa Carey

About the Royal Society Entrepreneur in Residence (EiR) Scheme

The Royal Society Entrepreneur in Residence (EiR) scheme, part of the Science, Industry and Translation programme, aims to increase the knowledge and awareness in UK universities of cutting edge industrial science, research and innovation. The successful applicants are funded to spend 20% of their time over two years with their host university and collaborators, sharing their experiences to help mentor and support students and academics. The scheme has now funded 49 placements in 29 universities across the UK since its inception in 2018.

Read more on the Royal Society website.

 

Similar stories

Alternating vaccines trial expands to include two additional vaccines

Clinical Trials Coronavirus COVID-19 General

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

Oxford medical students launch flagship raffle in aid of NHS heroes and lifesaving medical equipment

General

Tingewick, a society formed of medical students from Oxford University, are hosting a virtual charity raffle. With over 70 amazing prizes, ranging from Truck festival tickets to restaurant vouchers to bags of books and even a bike, the raffle is an exciting way to celebrate lockdown lifting by supporting many wonderful Oxfordshire businesses whilst raising lots of money for charity.

AIMday in Women's Health - registration for academics now open

Events Innovation

Are you an academic interested in finding out how your knowledge can be used to solve industry challenges? Would you like to widen your network? Meet potential collaborators / future employees? Gain insights into relevant funding schemes? If you answer YES to any of the above, now is the time to register for the AIMday in Women's Health.

UK and EU regulators conclude benefits of vaccination continue to outweigh the risks

Coronavirus COVID-19 General

Today, the medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.

Link between COVID-19 infection and subsequent mental health and neurological conditions found

Coronavirus COVID-19 General Research

One in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus, an observational study of more than 230,000 patient health records published in The Lancet Psychiatry journal estimates. The study looked at 14 neurological and mental health disorders.